Agios Pharmaceuticals | AGIO - Equity Capital And Reserves


Agios Pharmaceuticals reported $1.19B in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -3.27B 628M Dec/2025
Agios Pharmaceuticals USD 1.19B 91.22M Dec/2025
Alnylam Pharmaceuticals USD 789.18M 555.28M Dec/2025
Amgen USD 8.66B 961M Dec/2025
Arrowhead Research USD 568.42M 102.37M Dec/2025
Astellas Pharma JPY 1.76T 150.69B Dec/2025
AstraZeneca USD 48.67B 2.78B Dec/2025
Bayer EUR 29.7B 799M Sep/2025
Biogen USD 18.21B 573.5M Sep/2025
BioMarin Pharmaceutical USD 6.09B 30.29M Dec/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Daiichi Sankyo JPY 1.71T 57.86B Dec/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Exelixis USD 2.16B 619K Dec/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
Incyte USD 5.17B 516.28M Dec/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
Merck USD 51.85B 2.79B Sep/2025
Moderna USD 8.65B 680M Dec/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Novartis USD 44.75B 2.7B Sep/2025
Novartis USD 44.33B 2.28B Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sarepta Therapeutics USD 1.14B 179.5M Dec/2025
Vertex Pharmaceuticals USD 18.67B 1.35B Dec/2025